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Abstract
Purpose Tuberculous optic neuropathy may follow infec-
tion with Mycobacterium tuberculosis or administration of
the bacille Calmette–Guerin. However, this condition is not
well described in the ophthalmic literature.
Methods Ophthalmologists, identified through professional
electronic networks or previous publications, collected
standardized clinical data relating to 62 eyes of 49 patients
who they had managed with tuberculous optic neuropathy.
Results Tuberculous optic neuropathy was most commonly
manifested as papillitis (51.6 %), neuroretinitis (14.5 %),
and optic nerve tubercle (11.3 %). Uveitis was an additional
ocular morbidity in 88.7 % of eyes. In 36.7 % of patients,
extraocular tuberculosis was present. The majority of
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patients (69.4 %) had resided in and/or traveled to an en-
demic area. Although initial visual acuity was 20/50 or
worse in 62.9 % of 62 eyes, 76.7 % of 60 eyes followed
for a median of 12 months achieved visual acuities of 20/40
or better. Visual field defects were reported for 46.8 % of
eyes, but these defects recovered in 63.2 % of 19 eyes with
follow-up.
Conclusion Visual recovery from tuberculous optic neurop-
athy is common, if the diagnosis is recognized and appro-
priate treatment is instituted. A tuberculous etiology should
be considered when evaluating optic neuropathy in persons
from endemic areas.
Keywords Optic neuropathy . Tuberculosis . Presentation .
Visual outcome
Introduction
Tuberculous optic neuropathy includes multiple potential
optic nerve involvements that may follow infection with
Mycobacterium tuberculosis or vaccination or therapeutic
administration of the bacille Calmette–Guerin (i.e., attenuated
Mycobacterium bovis). After antimicrobial agents against M.
tuberculosis became available approximately 70 years ago,
patient survival improved and reports of clinical manifesta-
tions of tuberculous eye disease increased in the literature [1].
As summarized in the comprehensive review of intraocular
tuberculosis by Gupta et al. [2], unrelated case reports have
described various optic neuropathies in patients with tubercu-
losis, including neuroretinitis, papilledema, papillitis, optic
neuritis, retrobulbar neuritis, and optic nerve tubercle; disease
may reflect direct infection or an associated hypersensitivity
reaction. Published series of tuberculous optic neuropathy,
however, have totaled to less than ten patients and/or been
limited to patients with tuberculous meningitis.
To address the lack of information regarding the spec-
trum of tuberculous optic neuropathy that may present to the
ophthalmologist, a group of 13 neuro-ophthalmologists and
inflammatory eye disease specialists retrospectively collected
specified clinical data on 49 patients. The resultant data set
provides a description of types of optic nerve involvement and
associated eye disease, patient demographics, presenting
symptoms, methods of diagnosis, modes of treatment, and
visual outcomes.
Methods
Ophthalmologists who had managed cases of tuberculous
optic neuropathy were identified through postings on the
electronic communities of the American Uveitis Society, the
International Uveitis Study Group, the Association of Proctor
Fellows, and the North American Neuro-Ophthalmology
Society. In addition, authors of recently published cases of
tuberculous optic neuropathy were found through literature
searches using Ovid MEDLINE. Individuals were invited to
complete a data collection sheet that was approved by the
Oregon Health & Science University Institutional Review
Board for their patients with tuberculous optic neuropathy.
Contributing ophthalmologists were asked to submit the
following information: patient characteristics including gen-
der, age at presentation, ethnicity, countries of residence and
travel, and risk factors for contracting tuberculosis; optic nerve
involvement(s) (using the diagnoses listed by Gupta et al. [2],
i.e., optic nerve tubercle, papilledema, papillitis, optic neuritis,
retrobulbar neuritis, neuroretinitis, or other involvements);
other tuberculous ocular disease and systemic manifestations;
presenting symptom(s); duration of follow-up; visual acuity at
presentation and at final visit; and complications, including
visual field defects and optic atrophy. If any subject had also
suffered from uveitis or scleritis, description of the uveitis
according to SUNWorking Group criteria [3] or classification
of the scleritis per Watson and Hayreh [4] was required.
Criteria used to determine tuberculosis as the cause of the
optic neuropathy were requested, following the recommen-
dations of Gupta et al. [2] which were updated to include the
interferon-gamma (IFN-γ) release assay as an alternative to
the Mantoux skin test, per current guidelines [5]. These
criteria include: consistent ocular signs; positive Mantoux
reaction or IFN-γ release assay; active or old tuberculous
lesion on chest imaging; polymerase chain reaction (PCR)
detection of M. tuberculosis DNA in ocular fluid samples;
identification of acid-fast bacilli by microscopy or culture of
ocular or other tissue samples; and/or positive response to
four-drug anti-tuberculosis treatment (i.e., isoniazid, rifam-
picin, ethambutol and pyrazinamide). Information regarding
investigations undertaken to exclude other etiologies for the
optic neuropathy, as well as optic nerve or brain imaging
studies, was also collected. In addition, the pharmacological
approach was required.
Results
Clinical data were obtained from 13 providers at 11 oph-
thalmology clinics in 9 different countries relating to 49
patients and 62 eyes with a diagnosis of tuberculosis asso-
ciated optic neuropathy. Seven cases were previously pub-
lished as individual reports [6, 7] or in a case series [8]. The
cohort included 26 males (53 %) and 23 females (47 %),
with a median age at presentation of 36 years (range013–
76 years) (Table 1). The racial backgrounds of patients were
diverse, including Asian (n032, 65.3 %), White (n010,
20.4 %), and Black (n07, 14.3 %). Continents of residence
and/or travel of these individuals included Asia (n044,
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89.8 %), Europe (n014, 28.6 %), Africa (n08, 16.3 %), and
North America (n08, 16.3 %); some individuals resided in
or traveled to more than one continent. The most common
presenting ocular symptoms were decreased vision (n042,
85.7 %) and ocular pain (n013, 26.5 %), but some patients
had other complaints, including visual field defects, ptosis,
altered color vision, diplopia, ocular redness, and floaters
(n01–3, 2–6 %).
Following the description of potential optic nerve involve-
ments given by Gupta et al. [2], optic nerve involvement in 62
eyes of 49 patients was classified as: papillitis in 32 eyes
(51.6 %), neuroretinitis in 9 eyes (14.5 %), optic nerve tuber-
cle in 7 eyes (11.3 %), retrobulbar neuritis in 5 eyes (8.1 %),
and optic neuritis in 5 eyes (8.1 %) (Table 2). Other optic
nerve involvements, not included in this description, were:
compressive optic neuropathy in five eyes (8.1 %) and ante-
rior ischemic optic neuropathy in two eyes (3.2 %). Other
ocular involvements included: uveitis in 55 of 62 eyes
(88.7 %) and 37 of 49 patients (75.5 %), orbital apex syn-
drome in 8 eyes (12.9 %) of 8 patients (16.3 %), posterior
scleritis in 1 eye (1.6 %) of 1 patient (2.0 %), stromal keratitis
in 1 eye (1.6 %) of 1 patient (2.0 %), and central retinal vein
occlusion in 1 eye (1.6 %) of 1 patient (2.0 %). Other ocular
involvements were observed both in eyes affected with optic
neuropathy and in unaffected eyes. Per SUN criteria, of the 55
eyes with uveitis: 1 eye had anterior uveitis (1.8 %), 3 eyes
had intermediate uveitis (5.5 %), 34 eyes had posterior uveitis
(61.8 %), and 17 eyes had panuveitis (30.9 %). Onset of
Table 1 Characteristics of the study sample (n049 persons)
Variable Number of patients (%)
or median (range)
Gender
•Male 26 (53 %)
•Female 23 (47 %)
Age (years) 36 (13-76)
Laterality
•Unilateral 36 (73.5 %)
•Bilateral 13 (26.5 %)
Presenting symptoms
•Decreased vision 42 (85.7 %)
•Pain (includes ocular pain,
facial pain, headache)
13 (26.5 %)
•Visual field loss 3 (6.1 %)
•Ptosis 3 (6.1 %)
•Color vision loss 2 (4.1 %)
•Diplopia 2 (4.1 %)
•Ocular injection 2 (4.1 %)
•Floaters 2 (4.1 %)
•Othera 7 (14.3 %)
Race
•Asian 32 (65.3 %)
•White 10 (20.4 %)
•Black 7 (14.3 %)
Continents of residence or travel
•North America 8 (16.3)
•Europe 14 (28.6)
•Africa 8 (16.3)
•Asia 44 (89.8)
a Other: epiphora (n01), eyelid edema (n01), facial numbness (n01),
nasal congestion (n01), photophobia (n01), photopsia (n01), transient
visual obscuration (n01)
Table 2 Optic nerve and other ocular involvements (n062 eyes)
Number of eyes (%)
Optic nerve involvementsa
•Papillitis 32 (51.6 %)
•Neuroretinitis 9 (14.5 %)
•Optic nerve tubercle 7 (11.3 %)
•Compressive optic neuropathy 5 (8.1 %)
•Retrobulbar neuritis 5 (8.1 %)
•Optic neuritis 5 (8.1 %)
•Anterior ischemic optic neuropathy 2 (3.2 %)
•Papilledema 0 (0 %)
Other ocular involvementsa
•Uveitis 55 (88.7 %)
•Orbital apex syndrome 8 (12.9 %)
•Posterior scleritis 1 (1.6 %)
•Stromal keratitis 1 (1.6 %)
•Central retinal vein occlusion 1 (1.6 %)
Description of uveitis (n055 eyes)
Location
•Anterior 1 (1.8 %)
•Intermediate 3 (5.5 %)
•Posterior 34 (61.8 %)
•Panuveitis 17 (30.9 %)
Onset
•Sudden 29 (52.7 %)
•Insidious 26 (47.3 %)
Duration
•Limited 22 (40.0 %)
•Persistent 31 (56.4 %)
•Unspecified 2 (3.6 %)
Course
•Acute 21 (38.2 %)
•Recurrent 1 (1.8 %)
•Chronic 29 (52.7 %)
•Unspecified 4 (7.3 %)
aMultiple optic nerve or other ocular involvements were observed in
some patients
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uveitis was sudden in 29 (52.7 %) and insidious in 26 (47.3 %)
eyes. Duration of uveitis was limited in 22 (40.0 %), persistent
in 31 (56.4 %), and unspecified in 2 (3.6 %) eyes. The course
of uveitis was acute in 21 (38.2 %), recurrent in 1 (1.8 %),
chronic in 29 (52.7 %), and unspecified in 4 (7.3 %) eyes.
Criteria used to diagnose tuberculous optic neuropathy
included: consistent clinical signs (n049, 100 %); positive
Mantoux reaction (n038, 77.6 %); positive IFN-γ release
assay (n010, 20.4 %); tuberculous lesion on chest imaging
(n04, 8.2 %); identification of acid-fast bacilli by micros-
copy or culture of extraocular tissue samples (n03, 6.1 %);
and/or positive response to antituberculosis treatment (n0
44, 89.8 %), although in some cases such treatment was not
“four-drug”. Of the 49 patients, 32 individuals had disease
that was contiguous with the optic nerve, including uveitis,
posterior scleritis, orbital mass, and optic nerve tubercu-
loma. Of the 17 patients without such lesions, 10 individuals
had uveitis and 4 individuals showed evidence of extraocu-
lar tuberculosis. Of the remaining 3 patients, 1 patient was a
previously published case of tuberculous orbital apex
syndrome, [8] and 2 patients underwent testing for other
potential causes of the optic neuropathy. Applying the
guidelines for diagnosis of intraocular tuberculosis that were
defined by Gupta et al. [2] modified as described in the
“Methods”, all 49 cases were classified as “presumed” tu-
berculous optic neuropathy. Risk factors for tuberculosis in
the study group were: residence in and/or travel to an
endemic area (http://www.who.int/tb/publications/global_
report/2007/xls/global.xls.) (n034, 69.4 %), personal or
family history of tuberculosis (n09, 18.4 %), medical con-
ditions associated with susceptibility (i.e., diabetes mellitus,
n05, 10.2 % and malignancy, n01, 2.1 %), and health care
profession (n01, 2.1 %). Involvement of extraocular tissues
or organs outside the eye was reported in 18 of 49 persons
(36.7 %), including lung (n08, 16.3 %), meninges (n04,
8.2 %), lymph node (n04, 8.2 %), bone (n01, 2 %), and
kidney (n01, 2 %). These data are listed in Table 3.
The use of optic nerve or brain computerized axial to-
mography and magnetic resonance imaging, and the selec-
tion of investigations to exclude other etiologies for the
optic neuropathy, varied between cases. Overall, optic nerve
or brain imaging was performed in 19 patients (38.8 %). The
differential diagnosis of tuberculous optic neuropathy
depends on multiple factors that include the specific optic
involvement, the presence and type of other ocular pathology,
and geography. In addition, financial considerations may im-
pact which tests are ordered for a specific patient. Thus, the
approach to excluding other diagnoses for this series of
patients was necessarily heterogeneous, and consequently, it
was not possible to generate one standard algorithm for the
approach to the differential diagnosis of the optic neuropathy.
Taking into account the type of optic nerve involvement, and
detailed clinical history and examination findings, alternative
etiologies that were considered by the providers included
other infections (i.e., syphilis, toxoplasmosis, cat scratch dis-
ease, Lyme disease, leptospirosis, systemic fungal infection,
HIV-associated disease, and other forms of infectious menin-
gitis); systemic inflammatory diseases (i.e., multiple sclerosis,
neuromyelitis optica, sarcoidosis, Vogt–Koyanagi–Harada
syndrome, Behçet’s disease, and other systemic vasculitidies);
ocular inflammatory conditions (i.e., uveitis and posterior
scleritis); and vascular, neoplastic, toxic, and hereditary forms
of optic neuropathy.
Of the 49 patients, 47 individuals received antituberculosis
treatment (Table 4). One patient was lost to follow-up prior to
treatment, and another patient refused treatment. Management
was with four-drug antituberculosis treatment in 29 patients
(59.2 %) and with other antibiotic regimens in 18 patients
(36.7 %). In addition to antibiotics, 28 patients (57.1 %) were
treated with oral prednisone, with statedmaximum daily doses
varying between 20 and 120 mg. One patient received intra-
venous methylprednisolone in addition to oral prednisone.
Two other patients were given sub-Tenon’s corticosteroid
injections; one of these patients also took oral prednisone.
Snellen visual acuity was reported at presentation and, for
47 patients who were followed for a median of 12 months
(range01–81 months), at final visit (Table 5). For 62 eyes,
initial visual acuity was 20/40 or better in 23 eyes (37.1 %),
20/50 or worse in 39 eyes (62.9 %), and 20/200 or worse in
24 eyes (38.7 %). At final examination, 46 of 60 eyes
(76.7 %) achieved visual acuities of 20/40 or better, while
14 eyes (23.3 %) retained visual acuities of 20/50 or worse
and 6 eyes (10.0 %) retained visual acuities of 20/200 or
worse. There was no difference in achieving a visual acuity
of 20/40 or better for eyes treated with corticosteroid
(69.7 %) versus those not so treated (85.2 %) (p>0.05,
Fisher’s exact test, two-tailed). Of the 5 persons who either
did not receive treatment or did not have a positive response
to treatment, 2 patients were lost to follow-up. For the 3
affected eyes of the 3 remaining patients, visual acuity
improved at least two lines in 2 eyes and dropped at least
two lines in 1 eye. Numbers in individual groups were too
small for making meaningful correlations between optic
nerve involvement and visual acuity outcome. However, a
two-line improvement in visual acuity was reported for eyes
with each form of optic nerve involvement, with the excep-
tion of anterior ischemic optic neuropathy. Visual field
defects were documented in 29 eyes (45.2 %). The most
common defects were enlarged blind spot (n08, 27.6 %)
and central scotoma (n04, 13.8 %), but 12 different defects
were reported. The course of the visual field change was
known for 19 of these eyes: 6 eyes (31.6 %) experienced full
recovery, 6 eyes (31.6 %) experienced partial recovery, and
7 eyes (36.8 %) sustained permanent visual field defects.
Thirteen eyes (20.1 %) had evidence of optic atrophy on
examination.
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Discussion
Renewed interest in ocular tuberculosis has been evident in
the ophthalmic literature over the past decade [2, 9, 10]. This
attention is explained by factors that include: increasing prev-
alence of tuberculosis worldwide, recognition of M. tubercu-
losis as the etiological agent in specific subtypes of uveitis,
introduction of new diagnostic tools for the infection, and
emergence of drug-resistant tuberculosis. Published studies
have focused on uveitis, which is the most common ocular
manifestation of the infection. We sought to contribute to the
literature on ocular tuberculosis by describing the clinical
spectrum of optic nerve involvement.
In our series of 49 cases of tuberculous optic neuropathy,
the disease was typically unilateral, and the majority of
patients presented with painless loss of vision. More than
two thirds (69.4 %) of the affected individuals had resided in
and/or traveled to an endemic area for the infection. Nerve
involvements were diverse, but in approximately one half of
patients took the form of papillitis. Approximately 90 % of
eyes had uveitis, which in over 90 % of the cases was
posterior uveitis or panuveitis. Extraocular tuberculosis—
particularly pulmonary and meningeal—was present in
36.7 % of patients. The vast majority of patients received
treatment with antituberculosis antibiotics, and over one half
were also treated with corticosteroid. Visual outcomes were
generally good. At final review, 76.7 % of eyes achieved
visual acuities of 20/40 or better, and only 10.0 % of eyes
had visual acuities of 20/200 or worse. In addition, among
the 19 of 29 eyes that developed visual field defects and for
which follow-up was available, 63.2 % experienced com-
plete or partial recovery.
There are no diagnostic criteria designated for tubercu-
lous optic neuropathy specifically, and the diagnosis of
Table 3 Diagnosis, systemic
involvement and risk factors for
tuberculosis (n049 persons)
aOther systemic involvements:
bone (n01); renal (n01)
Variable Number of patients (%)
Criteria used for diagnosis of tuberculosis
•Consistent ocular signs 49 (100 %)
•Positive response to antituberculous treatment 44 (89.8 %)
•Positive Mantoux reaction 38 (77.6 %)
•Positive IFN-gamma release assay 10 (20.4 %)
•Active or old lesion(s) consistent with pulmonary tuberculosis on chest imaging 4 (8.2 %)
•Identification of acid-fast bacilli by microscopy or culture
•Extraocular 3 (6.1 %)
•Intraocular 0 (0 %)
•Positive M. tuberculosis PCR from ocular fluid 0 (0 %)
Systemic involvements
•Pulmonary 8 (16.3 %)
•Central nervous system: meningeal 4 (8.2 %)
•Lymphatic 4 (8.2 %)
•Othera 2 (4.1 %)
•None 31 (63.3 %)
Risk factors
•Lived in or travel to an endemic area 34 (69.4 %)
•Personal or family history of tuberculosis 9 (18.4 %)
•Diabetes mellitus 5 (10.2 %)
•Health care worker 1 (2.1 %)
•Malignancy 1 (2.1 %)
Table 4 Treatment regimens (n049 patients)
Treatment Number of patients (%)
Antibiotic alone 18 (36.7 %)
Corticosteroid alone 0 (0 %)
Antibiotic + corticosteroid 29 (59.2 %)
Nonea 2 (4.1 %)
Antibiotic
•Four-drug regimenb 29 (59.2 %)
•Other antituberculosis treatment 18 (36.7 %)
Corticosteroid
•Oral 28 (57.1 %)
•Intravenous 1 (2.0 %)
•Local 2 (4.1 %)
a None: lost to follow-up (n01); refused antituberculous treatment (n01)
b Four-drug regimen: isoniazid + rifampicin + pyrazinamide + ethambutol
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ocular tuberculosis in general continues to pose great diffi-
culty to ophthalmologists. Problems relate to the limitations
of all available tests, as well as the obvious difficulty in
taking a biopsy of affected intraocular tissues. These chal-
lenges were recently summarized in a comprehensive review
by Vasconcelos-Santos et al. [11] and further illustrated with
the series of clinicopathologically correlated cases reported by
Wroblewski et al. [12]. The situation has improved over the
past 10 years, with the successful commercialization of ocular
fluid analysis for bacterial DNA by the polymerase chain
reaction [13, 14] and tests of peripheral blood lymphocyte
reactivity toM. bacterium-specific antigens [15–17]. Howev-
er, while significant concerns remain, multiple different diag-
nostic criteria are currently in use. We followed the
recommendations of Gupta et al. [2] which can be summa-
rized as: consistent clinical signs; and positive results of ocular
investigations or positive results of systemic investigations or
therapeutic response to antituberculosis treatment; and
exclusion of other potential causes of uveitis. Using this set
of criteria, the clinician may define “confirmed” (i.e., with
positive results of ocular investigations) and “presumed”
cases. In the vast majority of cases [18], as also exemplified
by our series, the diagnosis of ocular tuberculosis is presumed.
Other diagnostic guidelines are more stringent, but also are
more difficult to use in practice due to the acknowledged
difficulty in obtaining ocular samples for testing [10, 19].
Different treatment regimens have been described for the
management of ocular tuberculosis, as reviewed by Gupta et
al. [2]. Recommendations published in 2003 by the US
Centers for Disease Control are that treatment of tuberculo-
sis should be with the combination of isoniazid, rifampicin,
pyrazinamide, and ethambutol [20]. A recent analysis of the
published literature suggests treatment of ocular tuberculo-
sis may vary from these guidelines at approximately half of
ophthalmology clinics around the world [21]. Four-drug
antituberculosis treatment was given in 59.2 % of our
patients, but all patients who agreed to treatment and/or
continued in follow-up received antimicrobial treatment.
We would like to highlight the importance of collaborating
with an infectious disease physician when managing tuber-
culous optic neuropathy, as has been emphasized by others
[2, 10, 11]. One unanswered question is: are patients with
tuberculous optic neuropathy treated with ethambutol and/or
isoniazid at increased risk of optic nerve toxicity, given an
already compromised optic nerve status? We did not observe
medication-induced optic neuropathy among the 31 patients
who received ethambutol plus isoniazid or the additional 16
patients who received isoniazid, but not ethambutol. How-
ever, we recommend patients be monitored closely for this
complication. Deterioration in color vision, visual acuity,
and/or visual field following initial improvement may indicate
drug toxicity. In addition, pyridoxine is routinely combined
with isoniazid to protect against peripheral neuropathy.
Systemic corticosteroid is frequently added to antimicro-
bial treatment of intraocular tuberculosis, although practice
patterns are not established [2, 10, 11]. Use of periocular
corticosteroid injections is also reported [18, 22]. Fifty-nine
percent of our patients received systemic or local corticoste-
roid as part of their treatment. This was always done con-
currently with antituberculosis therapy; it is clear that uveitis
occurring in the context of latent or manifest tuberculosis is
significantly more likely to recur when treated with cortico-
steroid alone [23]. We observed no significant difference in
numbers achieving 20/40 or better visual acuity for patients
treated with corticosteroid versus those not so treated, how-
ever. Interestingly, in their series of 157 patients with sus-
pected tuberculous uveitis, Ang et al. [17] also noted no
significant difference in outcomes between patients treated
with antituberculosis drugs combined with corticosteroid
therapy versus antituberculosis drugs alone. Despite these
results, we recognize the potential value of corticosteroid
Table 5 Snellen visual acuity and complications (n062 eyes)
Number of eyes (%)
Snellen visual acuity
Initial
(n062 eyes)
Final
(n060 eyes)
>20/50 23 (37.1 %) 46 (76.7 %)
≤20/50 39 (62.9 %) 14 (23.3 %)
≤ 20/200 24 (38.7 %) 6 (10.0 %)
Complications
Visual field defects 29 (46.8 %)
Defects (n029 eyes)
•Enlarged blind spot 8 (27.6 %)
•Central scotoma 4 (13.8 %)
•Altitudinal defect 2 (6.9 %)
•Peripheral defect 2 (6.9 %)
•Enlarged blind spot + paracentral
scotoma
2 (6.9 %)
•Central scotoma + peripheral defect 2 (6.9 %)
•Othera 6 (20.7 %)
•Not specified 3 (10.3 %)
Recovery (n029 eyes)
•Full 6 (20.7 %)
•Partial 6 (20.7 %)
•No 7 (24.1 %)
•Not specified 10 (34.5 %)
Optic atrophy 13 (21.0 %)
a Other: enlarged blind spot + central scotoma (n01), cecocentral
scotoma + peripheral defect (n01), paracentral scotoma (n01), altitu-
dinal defect + peripheral defect (n01), quadrantanopia (n01), 3-
quadrantanopia (n01)
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in reducing inflammation in selected cases of ocular tubercu-
losis, as has been widely reported [2, 9, 10]. We recommend
caution, however, when considering periocular injection of
long-acting corticosteroid, as the duration of action may ex-
tend beyond the course of antituberculosis treatment.
Limitations of our study include the retrospective nature
of data collection, ascertainment bias, and the difficulties of
studying a disease for which diagnostic criteria are not
established. On the other hand, our study represents a large
series of patients of tuberculous optic neuropathy, and stan-
dardized data collection has allowed us to summarize optic
nerve and other ocular involvements, presenting clinical
features, diagnostic and treatment approaches, and visual
acuity and visual field outcomes. The practical implications
of our study include the need for a high index of suspicion
for tuberculosis when evaluating optic neuropathy in
patients who have resided in or traveled to an endemic area.
Prior treatment of tuberculosis does not preclude the possi-
bility of recurrent infectious disease [24]. In 2010, the
Centers for Disease Control published their recommenda-
tion that either a tuberculin skin test or an IFN-γ release
assay be used in the routine diagnosis of M. tuberculosis
infection [5]. Our study also highlights the importance of
investigating for extraocular involvement, particularly pul-
monary or meningeal, when optic nerve disease is present.
Finally, a collaborative effort by the ophthalmologist and an
infectious disease physician in developing an antituberculo-
sis treatment schedule can result in a good visual outcome
for patients with tuberculous optic neuropathy.
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